Protalix BioTherapeutics, Inc.
PLX · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $14 | $18 | $19 | $20 |
| Short-Term Investments | $16 | $16 | $15 | $15 |
| Receivables | $14 | $9 | $5 | $3 |
| Inventory | $21 | $21 | $20 | $21 |
| Other Curr. Assets | $1 | $2 | $2 | $1 |
| Total Curr. Assets | $67 | $65 | $61 | $60 |
| Property Plant & Equip (Net) | $13 | $10 | $10 | $10 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $3 | $3 | $3 | $3 |
| Other NC Assets | $1 | $1 | $0 | $0 |
| Total NC Assets | $16 | $13 | $13 | $13 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $82 | $78 | $74 | $73 |
| Liabilities | – | – | – | – |
| Payables | $5 | $7 | $4 | $5 |
| Short-Term Debt | $1 | $1 | $1 | $2 |
| Tax Payable | $0 | $4 | $0 | $3 |
| Deferred Revenue | $0 | $0 | $2 | $0 |
| Other Curr. Liab. | $15 | $12 | $17 | $16 |
| Total Curr. Liab. | $22 | $24 | $24 | $26 |
| LT Debt | $7 | $4 | $4 | $4 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $1 | $1 | $1 | $1 |
| Total NC Liab. | $7 | $4 | $4 | $5 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $7 | $5 | $5 | $6 |
| Total Liabilities | $29 | $29 | $29 | $30 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | $0 | -$382 | -$382 | -$378 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $53 | $432 | $427 | $422 |
| Total Equity | $53 | $50 | $45 | $43 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $82 | $78 | $74 | $73 |
| Net Debt | -$5 | -$13 | -$14 | -$14 |